The Global Hashimoto’s Thyroiditis Drug Market is estimated to be valued at US$ 2.18 BN in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period from 2024 to 2031.

Key Takeaways


Key players operating in the Global Hashimoto’s Thyroiditis Drug Market are AbbVie Inc., Merck & Co., Allergan., Amneal Pharmaceuticals., Lannett Company, Mylan Pharmaceuticals, Pfizer, Akorn Pharmaceuticals, Acella Pharmaceuticals, Jerome Stevens Pharmaceuticals and Other Prominent Players. The key players are mainly focused on product approvals and launches to expand their regional presence. For instance, in February 2021, Allergan received FDA approval for levothyroxine sodium tablets for the treatment of hypothyroidism.

The growing prevalence of hypothyroidism disorders across the globe is propelling the Hashimoto's Thyroiditis Drugs Market Demand. According to the American Thyroid Association, approximately 20 million Americans have some form of thyroid problems. Moreover, hypothyroidism is nine times more common in women than in men.

Get More Insights on Hashimoto’s Thyroiditis Drug Market